{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:05Z","timestamp":1786979825060,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00228-018-2418-4","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T11:08:13Z","timestamp":1516792093000},"page":"655-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["The nocebo effect challenges the non-medical infliximab switch in practice"],"prefix":"10.1007","volume":"74","author":[{"given":"N. W.","family":"Boone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Romberg-Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Duijsens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Houwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. H. M.","family":"van der Kuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Janknegt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B. M.","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Winkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. A.","family":"van Bodegraven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"2418_CR1","unstructured":"European Medicines Agency (EMA). Guideline on similar biological medicinal products. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2014\/10\/WC500176768.pdf (accessed 14 November 2017)"},{"issue":"10","key":"2418_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ure\u00f1a S, Lim MJ, Lee YA, Lee SJ, Kim HU, Yoo DH, Braun J (2013) A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and effectiveness of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72(10):1605\u20131612. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203091","journal-title":"Ann Rheum Dis"},{"issue":"10086","key":"2418_CR3","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389(10086):2304\u20132316. https:\/\/doi.org\/10.1016\/S0140-6736(17)30068-5","journal-title":"Lancet"},{"issue":"10","key":"2418_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.cgh.2012.06.032","volume":"10","author":"I Ordas","year":"2012","unstructured":"Ordas I, Feagan BG, Sandborn WJ (2012) Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 10(10):1079\u20131087. https:\/\/doi.org\/10.1016\/j.cgh.2012.06.032","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2418_CR5","unstructured":"Handleiding behandeling IBD 2014-2015. Nederlandse Vereniging van Maag-, Darm- en leverartsen, oktober 2015. Available at: https:\/\/www.icc-ibd.com\/upload\/files\/DocumentvolledigHandleidingmetliteratuurvs7.21.pdf . Accessed 19 Jan 2018"},{"key":"2418_CR6","doi-asserted-by":"crossref","unstructured":"Nederlandse Vereniging voor Reumatologie (NVR). Standpunt NVR vergelijkbaarheid TNF remmers en plaatsbepaling biosimilar TNF remmers: Update 2015. Available at: https:\/\/www.nvr.nl\/wp-content\/uploads\/2015\/10\/Standpunt-NVR-vergelijkbaarheid-en-plaatsbepaling-biosimilar-TNF-remmers-2015.pdf (accessed 14 November 2017)","DOI":"10.1007\/s12467-016-0003-y"},{"key":"2418_CR7","unstructured":"Federatie Medisch Specialisten. Standpunt Biosimilars Federatie Medisch Specialisten. Available at: https:\/\/www.demedischspecialist.nl\/sites\/default\/files\/Standpunt%20Biosimilars%20Federatie%20Medisch%20Specialisten.PDF (accessed 14 November 2017)"},{"issue":"2","key":"2418_CR8","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1002\/prp2.208","volume":"4","author":"S Plan\u00e8s","year":"2016","unstructured":"Plan\u00e8s S, Villier C, Mallaret M (2016) The nocebo effect of drugs. Pharmacol Res Perspect 4(2):e00208. https:\/\/doi.org\/10.1002\/prp2.208","journal-title":"Pharmacol Res Perspect"},{"key":"2418_CR9","unstructured":"European Medicines Agency (EMA). Inflecta Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002778\/WC500151489.pdf (accessed 14 November 2017)"},{"key":"2418_CR10","unstructured":"European Medicines Agency (EMA). Remicade Summary of Product Characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000240\/WC500050888.pdf (accessed 14 November 2017)"},{"key":"2418_CR11","first-page":"579","volume":"20","author":"DM Heijde Van der","year":"1993","unstructured":"Van der Heijde DM, van\u2019t Hof M, van Riel PL et al (1993) Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20:579\u2013581","journal-title":"J Rheumatol"},{"key":"2418_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/rheumatology\/35.1.66","volume":"35","author":"S Jones","year":"1996","unstructured":"Jones S, Garrett C (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66\u201371","journal-title":"Br J Rheumatol"},{"issue":"8","key":"2418_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/apt.12030","volume":"36","author":"N Vande Casteele","year":"2012","unstructured":"Vande Casteele N, Buurman DJ, Sturkenboom MG et al (2012) Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 36(8):765\u2013771. https:\/\/doi.org\/10.1111\/apt.12030","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"2418_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W (2006) Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54(3):711\u2013715. https:\/\/doi.org\/10.1002\/art.21671","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2418_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0163278709338554","volume":"32","author":"BT West","year":"2009","unstructured":"West BT (2009) Analyzing longitudinal data with linear mixed models procedure in SPSS. Eval Health Prof 32(3):207\u2013228. https:\/\/doi.org\/10.1177\/0163278709338554","journal-title":"Eval Health Prof"},{"issue":"8","key":"2418_CR16","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg B, Sorensen IJ, Loft AG et al (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76(8):1426\u20131431. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210742","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2418_CR17","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s10620-017-4661-4","volume":"62","author":"LJT Smits","year":"2017","unstructured":"Smits LJT, Grelack A, Derikx LAAP, de Jong DJ, van Esch AAJ, Boshuizen RS, Drenth JPH, Hoentjen F (2017) Long term clinical outcomes after switching from Remicade to biosimilar CT-P13 in inflammatory bowel disease. Dig Dis Sci 62(11):3117\u20133122. https:\/\/doi.org\/10.1007\/s10620-017-4661-4","journal-title":"Dig Dis Sci"},{"key":"2418_CR18","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","volume":"15","author":"E Nikiphorou","year":"2015","unstructured":"Nikiphorou E, Kautiainen H, Hanonnen P et al (2015) Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade(infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 15:1677\u20131683","journal-title":"Expert Opin Biol Ther"},{"key":"2418_CR19","doi-asserted-by":"publisher","unstructured":"Severs M, Oldenburg B, Bodegraven AA et al (2017) The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis 11(3):289\u2013296. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw153","DOI":"10.1093\/ecco-jcc\/jjw153"},{"issue":"8","key":"2418_CR20","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1097\/MIB.0b013e318281f4c4","volume":"19","author":"EJ Eshuis","year":"2013","unstructured":"Eshuis EJ, Peters CP, Bodegraven AA et al (2013) Ten years of infliximab for Crohn\u2019s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis 19(8):1622\u20131630. https:\/\/doi.org\/10.1097\/MIB.0b013e318281f4c4","journal-title":"Inflamm Bowel Dis"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2418-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2418-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2418-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T15:31:41Z","timestamp":1570635101000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2418-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["2418"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2418-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"assertion":[{"value":"28 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"NB has been a consultant or provided paid lectures for Abbvie, Amgen, Biogen, Janssen-Cilag, Novartis, Pfizer, and Sandoz.LL has no conflict of interest to declare in relation to this study.MR has no conflict of interest to declare in relation to this study.LD and CH have no conflict of interest to declare in relation to this study.PHK has no conflict of interest to declare in relation to this study.RJ has no conflict of interest to declare in relation to this study.RP has no conflict of interest to declare in relation to this study.RL has no conflict of interest to declare in relation to this study.BW has no conflict of interest to declare in relation to this study.AAvB has been a consultant for medical issues or provided paid lectures for AbbVie, Biogen, Ferring, Janssen-Cilag, MSD, Pfizer, Samsung, Takeda, TEVA, and Tramedico.Guarantor of the article: AAvB","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}